GenSight Biologics S.A. (EPA: SIGHT)
France
· Delayed Price · Currency is EUR 0.319
+0.005 (1.59%)
Nov 19, 2024, 5:35 PM CET
GenSight Biologics Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 0.8 | 1.27 | 2.58 | 5.28 | 4.39 | 0.7 | Upgrade
|
| Other Revenue | 1.17 | 1.7 | 2.28 | 2.43 | 3.05 | 4.21 | Upgrade
|
| Revenue | 1.98 | 2.96 | 4.87 | 7.71 | 7.44 | 4.91 | Upgrade
|
| Revenue Growth (YoY) | -40.66% | -39.08% | -36.89% | 3.62% | 51.53% | 12.98% | Upgrade
|
| Gross Profit | 1.98 | 2.96 | 4.87 | 7.71 | 7.44 | 4.91 | Upgrade
|
| Selling, General & Admin | 8.32 | 13.3 | 13.36 | 12.92 | 9.99 | 6.5 | Upgrade
|
| Research & Development | 13.66 | 19.36 | 19.34 | 22.92 | 22.39 | 28.71 | Upgrade
|
| Operating Expenses | 21.98 | 32.66 | 32.7 | 35.84 | 32.37 | 35.21 | Upgrade
|
| Operating Income | -20.01 | -29.7 | -27.84 | -28.13 | -24.93 | -30.3 | Upgrade
|
| Interest Expense | -2 | -3.15 | -2.65 | -2.17 | -1.72 | -0.41 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.02 | -0.21 | 0.65 | 0.37 | -0.09 | -0.02 | Upgrade
|
| Other Non Operating Income (Expenses) | 1.93 | 6.84 | 2.21 | 1.31 | -7.27 | -0.14 | Upgrade
|
| EBT Excluding Unusual Items | -20.1 | -26.22 | -27.62 | -28.62 | -34.01 | -30.86 | Upgrade
|
| Pretax Income | -20.1 | -26.22 | -27.62 | -28.62 | -34.01 | -30.86 | Upgrade
|
| Income Tax Expense | 0 | - | 0.01 | 0 | 0 | 0 | Upgrade
|
| Net Income | -20.11 | -26.22 | -27.63 | -28.62 | -34.02 | -30.87 | Upgrade
|
| Net Income to Common | -20.11 | -26.22 | -27.63 | -28.62 | -34.02 | -30.87 | Upgrade
|
| Shares Outstanding (Basic) | 67 | 48 | 46 | 45 | 35 | 28 | Upgrade
|
| Shares Outstanding (Diluted) | 67 | 48 | 46 | 45 | 35 | 28 | Upgrade
|
| Shares Change (YoY) | 44.26% | 4.29% | 2.61% | 28.54% | 23.76% | 16.00% | Upgrade
|
| EPS (Basic) | -0.30 | -0.54 | -0.60 | -0.63 | -0.97 | -1.09 | Upgrade
|
| EPS (Diluted) | -0.30 | -0.54 | -0.60 | -0.63 | -0.97 | -1.09 | Upgrade
|
| Free Cash Flow | -15.81 | -24.67 | -34.01 | -17.17 | -15.05 | -28.18 | Upgrade
|
| Free Cash Flow Per Share | -0.24 | -0.51 | -0.73 | -0.38 | -0.43 | -0.99 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -1012.40% | -1001.86% | -572.15% | -364.86% | -335.13% | -617.09% | Upgrade
|
| Profit Margin | -1017.51% | -884.62% | -567.83% | -371.22% | -457.19% | -628.68% | Upgrade
|
| Free Cash Flow Margin | -800.15% | -832.42% | -698.97% | -222.74% | -202.28% | -573.95% | Upgrade
|
| EBITDA | -19.21 | -28.31 | -26.77 | -27.2 | -24.01 | -29.31 | Upgrade
|
| D&A For EBITDA | 0.79 | 1.39 | 1.06 | 0.93 | 0.93 | 0.99 | Upgrade
|
| EBIT | -20.01 | -29.7 | -27.84 | -28.13 | -24.93 | -30.3 | Upgrade
|
| Revenue as Reported | 1.98 | 2.96 | 4.87 | 7.71 | 7.44 | 4.91 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.